Mam­moth Bio­sciences teams with GSK to put Covid-19 CRISPR tests at home, air­ports, bor­ders

The old CRISPR ri­val­ry is back in pan­dem­ic fash­ion.

Two weeks af­ter Feng Zhang-found­ed Sher­lock Bio­sciences launched the first Covid-19 CRISPR test, Jen­nifer Doud­na-found­ed Mam­moth Bio­sciences has part­nered with Glax­o­SmithK­line on their own tests, with plans to even­tu­al­ly roll it out in places like homes and air­ports. Take a swab, get a green light, and you’re good to board.

“You can al­so imag­ine about build­ing a com­pan­ion app, so you’re con­nect­ing to next steps or tele­health” if you test pos­i­tive, Mam­moth CEO and co-founder Trevor Mar­tin told End­points News. “There’s a lot of op­por­tu­ni­ty to re­al­ly in­te­grate in­to the broad­er ecosys­tem. That’s why we’re work­ing with an or­ga­ni­za­tion like GSK — they ob­vi­ous­ly have a glob­al reach to un­der­stand dif­fer­ent needs, how to scale, and are plugged in­to this broad­er ecosys­tem.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA